Rancho Santa Margarita, CA (PRWEB) June 05, 2017
As chemotherapy treatment regimens are increasingly administered in the form of oral drugs, practices and patients are currently facing new challenges to ensure safety, monitoring, and adherence to new regimens.
Studies have shown that 80% of patients on oral oncolytics have less than optimal adherence to their treatment regimens and that medication adherence generally decreases over time, even with patients that are considered low risk for noncompliance. (1)
Considering the critical nature of chemotherapy treatment as it relates to successful patient outcomes, new technologies are required to assist patients in managing their medications, reporting side effects and collecting data that can be used to better create an ongoing comprehensive overview of an individual patient situation – driving improved medication adherence and overall patient outcomes.
Willowglade Technologies is addressing this issue head on by actively engaging the patients via the Health OrchestratorTM and the Personal Health NavigatorTM mobile application. Willowglades’ comprehensive platform is built on four pillars of patient involvement, namely Collaboration, Communication, Education and Adherence.
“As studies have shown, building and managing a comprehensive view of the patient is critical to medication adherence programs (2)” said John Papandrea, CEO and President of Willowglade Technologies. “Risk stratification strategies, managing patient reported outcomes (PROs), proving patient specific educational content and monitoring medication usage provides the broad spectrum of functions required for the implementation of a successful and comprehensive adherence program” he said.
The Willowglade Technologies platform was specifically designed with the intent of “involving” the patient in their own care. By taking this unique approach, the patient is an active member of their own “care team” - contributing data and patient reporting outcomes. As such, the patient feels they contribute much more on their road to recovery, will adhere to medication regimens more closely and ultimately drive superior outcomes for themselves as well with their surrounding clinical team.
This announcement is made during the American Society of Clinical Oncology (ASCO) conference to be held in Chicago, June 2-6, 2017. To learn more about Willowglade Technologies contact us at info(at)willowgladetechnologies.com
About Willowglade Technologies Corporation. Willowglade Technologies is a provider of technology solutions to the healthcare community, with a focus on enabling involving the patient in their care from “Clinical Trial to Clinical Care.”
No part of this publication may be reproduced or transmitted in any form or for any purpose without the express permission of Willowglade Technologies Corporation. The information contained herein may be changed without prior notice. Some software products marketed by Willowglade Technologies Corporation may contain software components licensed from other software vendors. Willowglade Technologies and Willowglade Technologies products and services mentioned herein, as well as their respective logos are trademarks or registered trademarks of Willowglade Technologies Corporation. “Willowglade Technologies", "Personalized Patient Experience", "Empowering Patient Recovery", the Tree Logo, the CJA logo, "cancerjourneyapps.com" “From Clinical Trial to Clinical Care”, “Health Orchestrator”, “Personal Health Navigator” and "because every cancer diagnosis is a journey" are trademarks of Willowglade Technologies Corporation.
Willowglade Technologies – 29822 Avenida de las Banderas, Suite A, Rancho Santa Margarita, CA, 92688.